Shareholder Alert: Ademi LLP investigates whether Constellation Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with MorphoSys

MILWAUKEE, June 2, 2021 /PRNewswire/ -- Ademi LLP is investigating Constellation (Nasdaq: CNST) for possible breaches of fiduciary duty and other violations of law in its transaction with MorphoSys.

Click here to learn how to join the action: https://www.ademilaw.com/case/constellation-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges Constellation's financial outlook is excellent and yet Constellation shareholders will receive only $34 for each share of Constellation common stock. The merger agreement unreasonably limits competing bids for Constellation by prohibiting solicitation of further bids, and imposing a termination penalty if Constellation accepts a superior bid. Constellation insiders will receive millions of dollars as part of change of control arrangements. We are investigating the conduct of Constellation's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Constellation.

If you own Constellation common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/constellation-pharmaceuticals-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP